Phase 1

The phase I program at the University of Arizona Cancer Center conducts cutting-edge early clinical trials across a broad spectrum of solid and hematologic cancers for patients whose cancer progressed on standard chemotherapy. Our phase I team provide patients with a comprehensive and unique care approach focused on cancer treatment, nutrition, optimal physical activity, and mental health wellbeing through diverse specialists and support groups at our cancer center. Our team is comprised of outstanding oncologists/investigators, investigational pharmacists, nurse practitioners, research nurses, and research coordinators with several years of experience whose main focus is patient care and providing best therapeutic options through discovery.

The Early Phase clinical trials team goals:

  • Provide patients with world-class compassionate care through a dedicated multidisciplinary team approach.
  • Conduct innovative cutting-edge early clinical trials across a broad spectrum of hematologic and solid cancers.
  • Conduct comprehensive genetic testing through expanded molecular profiling to identify targetable mutations for cancers.
  • Our phase I lab scientist strive to develop new drugs to fight cancer and identify new biomarkers to assess response to treatment.
  • Access to a genetic counselor to test for hereditary diseases.
  • To educate the next generation of investigators and oncologists.

Featured Clinical Trials

An Open-Label, Multicenter, Dose Escalation, Phase IA/IB Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Alpha (FAP), as a Single Agent (Part A) or in Combination with Trastuzumab or Cetuximab (Part B or C)

A Phase 1 Study of E6201 for the Treatment of Central Nervous System Metastases (CNS) From BRAF or MEK-Mutated Metastatic Melanoma

A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Positive Solid Tumors

Tucson

Medical Oncology
Medical Oncology

Phoenix

Medical Oncology
Gynecologic Oncology
Medical Oncology

Staff

Tucson

Clinical Research Nursing

Erica Castillo, RN, BSN
520-694-9089
Diane Rensvold, RN
520-694-9055
Lynnette Theiss, Senior Research RN
520-694-9062

Clinical Research Coordination

Jose Armando Bermudez Rodriguez
520-694-1231

Research Data Coordination

Janet Huynh, BA
520-626-7361
Samuel S Kraus, BHS

Regulatory Coordination

Ruth Cañamar, BA
520-626-6515
Sarah Martinez, MPH
(520) 626-9756

Admin Support

Lora Macias
520-626-7866